The news of Morgan Stanley reiterating an Equal-Weight rating on BioNTech and maintaining a $124 price target is neutral for the stock. The rating suggests that the stock is fairly valued and the price target remains unchanged, indicating no significant change in the analyst's outlook. This is unlikely to have a major impact on the stock price in the short term.